down arrow

Allakos, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US01671P1003
USD
0.33
0.00 (0.00%)

May 16

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.221.55
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Mar 2025)

FII

10.13%

Held by 70 FIIs

DII

48.63%

Held by 34 DIIs

Promoter

16.89%

How big is Allakos, Inc.?

22-Jun-2025

As of May 16, Allakos, Inc. has a market capitalization of 29.40 million, with net sales of 0.00 million and a net profit of -70.85 million over the latest four quarters. As of December 2024, shareholder's funds were 78.82 million, and total assets were 96.60 million.

Market Cap: As of May 16, Allakos, Inc. has a market capitalization of 29.40 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Allakos, Inc. reported net sales of 0.00 million and a net profit of -70.85 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds amounted to 78.82 million, while total assets were reported at 96.60 million.

Read More

What does Allakos, Inc. do?

22-Jun-2025

Allakos, Inc. is a clinical-stage biotechnology company focused on developing antibodies targeting mast cells and eosinophils. It has a market cap of $29.40 million and reported a net profit loss of $26 million as of March 2025.

Overview:<BR>Allakos, Inc. is a clinical-stage biotechnology company engaged in developing antibodies that selectively target mast cells and eosinophils within the pharmaceuticals industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 29.40 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 97.55%<BR>Debt Equity: -1.00<BR>Return on Equity: -170.81%<BR>Price to Book: 0.53<BR><BR>Contact Details:<BR>Address: 975 Island Dr Ste 201, REDWOOD CITY CA: 94065-5173<BR>Tel: 1 650 5975002<BR>Website: http://www.allakos.com/

Read More

Who are in the management team of Allakos, Inc.?

22-Jun-2025

As of March 2022, the management team of Allakos, Inc. includes Daniel Janney (Independent Chair), Dr. Robert Alexander (CEO and Director), and Independent Directors Robert Andreatta, Natalie Holles, Steven James, and John McKearn, who oversee the company's strategic direction and governance.

As of March 2022, the management team of Allakos, Inc. includes the following individuals:<BR><BR>- Mr. Daniel Janney, who serves as the Independent Chair of the Board.<BR>- Dr. Robert Alexander, who is the Chief Executive Officer and a Director.<BR>- Mr. Robert Andreatta, who is an Independent Director.<BR>- Ms. Natalie Holles, who is also an Independent Director.<BR>- Mr. Steven James, who serves as an Independent Director.<BR>- Mr. John McKearn, who is an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and governance of the company.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 29 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

97.55%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

-170.81%

stock-summary
Price to Book

0.53

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-26 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.24%
0%
5.24%
6 Months
-71.63%
0%
-71.63%
1 Year
-77.3%
0%
-77.3%
2 Years
-93.06%
0%
-93.06%
3 Years
-89.68%
0%
-89.68%
4 Years
-99.67%
0%
-99.67%
5 Years
-99.51%
0%
-99.51%

Allakos, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0.12%
EBIT to Interest (avg)
-150.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.53
EV to EBIT
0.26
EV to EBITDA
0.30
EV to Capital Employed
-25.83
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
97.55%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-170.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 30 Schemes (24.35%)

Foreign Institutions

Held by 70 Foreign Institutions (10.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 63.15% vs -67.69% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.50",
          "val2": "-44.60",
          "chgp": "58.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-27.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.20",
          "val2": "-71.10",
          "chgp": "63.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 37.64% vs 41.97% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-111.00",
          "val2": "-189.90",
          "chgp": "41.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-115.80",
          "val2": "-185.70",
          "chgp": "37.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-18.50
-44.60
58.52%
Interest
0.00
0.00
Exceptional Items
0.00
-27.30
100.00%
Consolidate Net Profit
-26.20
-71.10
63.15%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 63.15% vs -67.69% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-111.00
-189.90
41.55%
Interest
0.00
0.00
Exceptional Items
-3.50
0.00
Consolidate Net Profit
-115.80
-185.70
37.64%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 37.64% vs 41.97% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Allakos, Inc. stock-summary
stock-summary
Allakos, Inc.
Pharmaceuticals: Major
Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
Company Coordinates stock-summary
Company Details
975 Island Dr Ste 201 , REDWOOD CITY CA : 94065-5173
stock-summary
Tel: 1 650 5975002
stock-summary
http://www.allakos.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."